Assertio
Lake Forest · Founded 1995
About Assertio
Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor (diclofenac potassium) liquid-filled capsules for relief of mild to moderate acute pain, and Lazanda (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.
Company Facts
- Founded: 1995
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $1.0B
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2022)
- Ticker: nasdaq:ASRT
- Website: assertiotx.com
- Phone: 224.419.7106
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/assertio-139310 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.